The company picked up the Pharm Exec Brand of the Year award last week at the iPharma event in New York.
Gilead's Senior Director for HCV Marketing, Jason Levine, proudly accepted the Pharm Exec Brand of the Year award last week at iPharma 2015.
Pharm Exec's 31 Editorial Advisory Board (EAB) members voted unanimously for the two-punch hepatitis C treatment, Sovaldi and Harvoni, to take this year's title. They were by Gilead Science’s commitment to a strong franchise in anti-viral therapies through clinically useful drug combinations whose tolerability appeals to patients, and by the $10.3 billion in US sales posted by Sovaldi in 2014!
Pharm Exec Editor-in-Chief William Looney was on hand to present Jason with his award at a glittering event at Broadway's Crown Plaza Hotel in New York.
For the full story of Pharm Exec's 2015 Brand of the Year, click here.
Gilead's Senior Director for HCV Marketing, Jason Levine (left), accepts the Pharm Exec Brand of the Year award from Editor-in-Chief William Looney.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.